Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00036972 · ClinicalTrials.gov registry record · Phase 1
Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
NCT00036972: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00036972 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00036972, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma. PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy before and after surgery in treating patients who have recurrent malignant glioma.
Interventions
- PROCEDURE conventional surgery
- PROCEDURE adjuvant therapy
- BIOLOGICAL cintredekin besudotox
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-11 |
| Est. Completion | 2009-12 |
| Phase | Phase 1 |
What the finished NCT00036972 record still lists
NCT00036972 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 4 interventions - of which conventional surgery is the first listed.
NCT00036972 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00036972 about?
NCT00036972 is a clinical study titled "Immunotoxin Therapy Before and After Surgery in Treating Patients With Recurrent Malignant Glioma". RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. Immunotoxin therapy may be effective in treating malignant glioma. PURPOSE: Phase I trial to study the effectiveness of immunotoxin therapy before and after surgery in treating patients who have recurrent mal...
What is the current status of trial NCT00036972?
This trial is currently completed. It is a Phase 1 study. The study started on 2001-11. Estimated completion is 2009-12.
What interventions are being tested in trial NCT00036972?
The interventions under investigation include: conventional surgery (PROCEDURE), adjuvant therapy (PROCEDURE), cintredekin besudotox (BIOLOGICAL), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00036972?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia